Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

BACKGROUND: Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as salvage therapy in relapsed small cell lung cancer (SCLC). We conducted this signal-finding study to assess the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pakkala, Suchita, Higgins, Kristin, Chen, Zhengjia, Sica, Gabriel, Steuer, Conor, Zhang, Chao, Zhang, Guojing, Wang, Shuhua, Hossain, Mohammad S, Nazha, Bassel, Beardslee, Tyler, Khuri, Fadlo R, Curran, Walter, Lonial, Sagar, Waller, Edmund K, Ramalingam, Suresh, Owonikoko, Taofeek K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754662/
https://www.ncbi.nlm.nih.gov/pubmed/33428583
http://dx.doi.org/10.1136/jitc-2020-001302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754662/
https://www.ncbi.nlm.nih.gov/pubmed/33428583
http://dx.doi.org/10.1136/jitc-2020-001302

Ejemplares similares